NomosLogic builds clinical genomics infrastructure for health systems, pharmaceutical research organizations, and health plans.

Personalized molecular medicine infrastructure: deterministic, anchored systems for pharmacogenomics, clinical decision support, and molecularly grounded research.

We process DNA through 496,805 proprietary variant mappings and 1.2 million clinical rules — delivering pharmacogenomic decision support in 130 seconds. Industry standard: 7–14 days.

40% of people metabolize medications differently due to genetic variation. 362+ FDA drug-gene interactions exist. <7% of patients are tested. The signals are there. The infrastructure to act on them was not. We built it.

For providers: real-time variant interpretation, drug-gene alerts, dosing guidance, and prescriber-ready reports mapped to CPIC/FDA evidence. Deterministic — same input, same output. SMART on FHIR integrated.

For pharma: PROTEUS models evolutionary drug resistance across populations. Zero genomic data leaves the compute boundary. Drug candidate profiling, companion Dx support, cohort stratification, pharmacovigilance.

For health plans: preemptive pharmacogenomic screening to reduce adverse events, eliminate ineffective trials, and support formulary optimization at population scale.

For consumers: DendriteLite turns dormant 23andMe/Ancestry/MyHeritage DNA into clinical-grade health reports with Chiron, our AI genomic health agent.

Core stack: Hardy Bridge (496K variant translation engine), COVENANT (30-sec genome resolution), TRINITY (multi-omic fusion across 1.2M clinical rules), PROTEUS (evolutionary simulation). 14 patents in filing via WSGR.

HIPAA compliant. Zero-knowledge identity architecture. Enterprise-ready.

Founded by Matt Hardy CEO, Salt Lake City, Utah.

Website
https://www.nomoslogic.com
Industry
Biotechnology Research